Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.

It is critically important for oncology care providers to be aware of the best ways to incorporate these advances into standard practice so that each patient can receive optimal care.

To help patients have the best outcomes possible, clinicians need education on selection of therapy (high-intensity, low-intensity, or targeted) and on how best to manage toxicities and provide supportive care.

Clinicians must understand the treatment evolution and guidelines for when to administer two-, three-, or four drug regimens as initial or subsequent therapy in context of the patient's therapeutic and disease history. In addition, it is important for clinicians to educate patients about their different treatment options (e.g., administration and adverse events) and discuss patient preferences and individual circumstances that may affect treatment recommendations.